Click on headlines below to download research

First signs of efficacy coming up
Sunesis Pharmaceuticals | 22/03/2019

Sunesis is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first signs of clinical efficacy…

Shorty Creek potential validated by South32
Freegold Ventures | 22/03/2019

Freegold Ventures has granted South32 (an A$19.0bn market cap major demerged from BHP in 2015) an option to earn up to a 70% interest in Shorty Creek by…

New investments ahead
Deutsche Beteiligungs | 21/03/2019

Deutsche Beteiligungs (DBAG) is making steady progress on its investment agenda, with three new acquisitions and several follow-on funding rounds totalling…

Potential delay to nootkatone
Evolva | 21/03/2019

Evolva has received a letter from the US Environmental Protection Agency (EPA), which has identified a study for which it could not complete its review,…

IMO 2020 on the horizon
Hellenic Petroleum | 21/03/2019

Changes to bunker fuel regulation to be implemented on 1 January 2020 by the International Maritime Organization (IMO) will have major implications for…

Full-year results and near-term trial initiations
Auris Medical Holding | 21/03/2019

Auris recently announced its full-year 2018 financial results and provided an update on its active intranasal betahistine programs. R&D expenditure…

Executive interview - Actinogen Medical
Executive interview - Actinogen Medical | 21/03/2019

Actinogen Medical is an ASX-listed biotech developing its lead…

Good performance in a challenging market
Game Digital | 21/03/2019

Game Digital’s (GMD’s) core retail business performed well in a challenging market, with material planned cost savings absorbing an anticipated…